AbCellera Biologics Inc (ABCL)

Form 8-K - Current report

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. “Dr...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in...

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including...

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera (Nasdaq: ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at...

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans